Cyclophosphamide as a potent inhibitor of tumor thioredoxin reductase in vivo

Toxicology and Applied Pharmacology

Volumn 218, Issue 1, 2007, Pages 88-95

  Wang, Xufang ^a   Zhang, Jinsong ^a   Xu, Tongwen ^a  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

Cyclophosphamide; Thioredoxin; Thioredoxin reductase

Indexed keywords

CATALASE; CYCLOPHOSPHAMIDE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; SUPEROXIDE DISMUTASE; THIOREDOXIN; THIOREDOXIN REDUCTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; LEWIS CARCINOMA; LIVER CELL CARCINOMA; MALE; NONHUMAN; OXIDATION REDUCTION REACTION; SINGLE DRUG DOSE; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ASCITES; CARCINOMA, LEWIS LUNG; CATALASE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; ENZYME INHIBITORS; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED C57BL; OXIDATION-REDUCTION; SUPEROXIDE DISMUTASE; THIOREDOXIN REDUCTASE (NADPH); TIME FACTORS;

MUS;

EID: 33845914554     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2006.10.029     Document Type: Article

References (38)

1. Andersson M., Holmgren A., and Spyrou G. NK-lysin, a disulfide-containing effector peptide of T-lymphocytes, is reduced and inactivated by human thioredoxin reductase. Implication for a protective mechanism against NK-lysin cytotoxicity. J. Biol. Chem. 271 (1996) 10116-10120
2. Anestal K., and Arnér E.S.J. Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine. J. Biol. Chem. 278 (2003) 15966-15972
3. Arnér E.S.J., and Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem. 267 (2000) 6102-6109
4. Arnér E.S.J., Nordberg J., and Holmgren A. Biochem. Biophys. Res. Commun. 225 (1996) 268-274
5. Biswal S., Maxwell T., Rangasamy T., and Kehrer J.P. Modulation of benzo[a]pyrene-induced p53 DNA activity by acrolein. Carcinogenesis 24 (2003) 1401-1406
6. Casso D., and Beach D. Mol. Gen. Genet. 252 (1996) 518-529
7. Cenas N., Prast S., Nivinskas H., Sarlauskas J., and Arnér E.S.J. Interactions of nitroaromatic compounds with the mammalian selenoprotein thioredoxin reductase and the relation to induction of apoptosis in human cancer cells. J. Biol. Chem. 281 (2006) 5593-5603
8. Chen Z.H., Saito Y., Yoshida Y., Sekine A., Noguchi N., and Niki E. 4-Hydroxynonenal induces adaptive response and enhances PC12 cell tolerance primarily through induction of thioredoxin reductase 1 via activation of Nrf2. J. Biol. Chem. 280 (2005) 41921-41927
9. Claiborne A. Catalase activity. In: Greenwald R.A. (Ed). CRC Handbook of Methods for Oxygen Radical Research (1985), CRC Press, Boca Raton 283-284
10. Colvin O.M. An overview of cyclophosphamide development and clinical applications. Curr. Pharm. Des. 5 (1999) 555-560
11. Dong Q., Bullock N., Ali-Osman F., Colvin O.M., Bigner D.D., and Friedman H.S. Repair analysis of 4-hydroperoxycyclophosphamide-induced DNA interstrand crosslinking in the c-myc gene in 4-hydroperoxycyclophosphamide-sensitive and -resistant medulloblastoma cell lines. Cancer Chemother. Pharmacol. 37 (1996) 242-246
12. Ellman G.L. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 82 (1959) 70-77
13. Fang J.G., Lu J., and Holmgren A. Thioredoxin reductase is irreversibly modified by curcumin-A novel molecular mechanism for its anticancer activity. J. Biol. Chem. 280 (2005) 25284-25290
14. Fraiser L.H., Kanekal S., and Kehrer J.P. Cyclophosphamide toxicity. Characterising and avoiding the problem. Drugs 42 (1991) 781-795
15. Friedman H.S., Pegg A.E., Johnson S.P., Loktionova N.A., Dolan M.E., Modrich P., Moschel R.C., Struck R., Brent T.P., Ludeman S., Bullock N., Kilborn C., Keir S., Dong Q., Bigner D.D., and Colvin O.M. Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase. Cancer Chemother. Pharmacol. 43 (1999) 80-85
16. Habig W.H., Pabst M.J., and Jakoby W.B. Glutathione-S-transferases: the first enzymatic step in mercapturic acid formation. J. Biol. Chem. 249 (1974) 7130-7139
17. Holmgren A. Thioredoxin and glutaredoxin systems. J. Biol. Chem. 264 (1989) 13963-13966
18. Holmgren A., and Bjornstedt M. Thioredoxin and thioredoxin reductase. Methods Enzymol. 252 (1995) 199-208
19. Lee S.M., Crowther D., Scarffe J.H., Dougal M., Elder R.H., Rafferty J.A., and Margison G.P. Cyclophosphamide decreases O6-alkylguanine-DNA alkyltransferase activity in peripheral lymphocytes of patients undergoing bone marrow transplantation. Br. J. Cancer 66 (1992) 331-336
20. Matar P., Rozados V.R., Gonzalez A.D., Dlugovitzky D.G., Bonfil R.D., and Scharovsky O.G. Mechanism of antimetastatic immunopotentiation by low-dose cyclophosphamide. Eur. J. Cancer 36 (2000) 1060-1066
21. May J.M., Mendiratta S., Hill K.E., and Burk R. Reduction of dehydroascorbate to ascorbate by the selenoenzyme thioredoxin reductase. J. Biol. Chem. 272 (1997) 22607-22610
22. Moore M.J. Clinical pharmacokinetics of cyclophosphamide. Clin. Pharmacokinet. 20 (1991) 194-208
23. Nguyena P., Awwada R.T., Smarta D.D.K., Spitzb D.R., and Giusa D. Thioredoxin reductase as a novel molecular target for cancer therapy. Cancer Lett. 236 (2006) 164-174
24. Nordberg J., and Arnér E.S.J. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radical Biol. Med. 31 (2001) 1287-1312
25. Park Y.S., Fujiwara N., Koh Y.H., Miyamoto Y., Suzuki K., Honke K., and Taniguchi N. Induction of thioredoxin reductase gene expression by peroxynitrite in human umbilical vein endothelial cells. Biol. Chem. 383 (2002) 683-691
26. Park Y.S., Misonou Y., Fujiwar N., Takahashi M., Miyamoto Y., Koh Y.M., Suzuki K., and Taniguch N. Induction of thioredoxin reductase as an adaptive response to acrolein in human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 327 (2005) 1058-1065
27. Rotruck J.T., Pope A.L., Ganther H.E., Swanson A.B., Hafeman D.G., and Hoekstra W.G. Selenium: biochemical role as a component of glutathione peroxidase. Science 179 (1973) 588-590
28. Saitoh M., Nishitoh H., Fujii M., Takeda K., Tobiume K., Sawada Y., Kawabata M., Miyazono K., and Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 17 (1998) 2596-2606
29. Sakurai A., Nishimoto M., Himeno S., Imura N., Tsujimoto M., Kunimoto M., and Hara S. Transcriptional regulation of thioredoxin reductase 1 expression by cadmium in vascular endothelial cells: role of NF-E2-related factor-2. J. Cell. Physiol. 203 (2005) 529-537
30. Sasada T., Nakamura H., Ueda S., Sato N., Kitaoka Y., Gon Y., Takabayashi A., Spyrou G., Holmgren A., and Yodoi J. Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II). Free Radical Biol. Med. 27 (1999) 504-514
31. Schwartz P.S., and Waxman D.J. Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Mol. Pharmacol. 60 (2001) 1268-1279
32. Sun Y., Larry W., Oberley W., and Ying L. A simple method for clinical assay of superoxide dismutase. Clin. Chem. 34 (1988) 497-500
33. Witte A.B., Anestal K., Jerremalm E., Ehrsson H., and Arnér E.S.J. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radical Biol. Med. 39 (2005) 696-703
34. Yang X.M., Wu X.L., Choi Y.E., Kern J.C., and Kehrer J.P. Effect of acrolein and glutathione depleting agents on thioredoxin. Toxicology 204 (2004) 209-218
35. Yoo M.H., Xu X.M., Carlson B.A., Gladyshev V.N., and Hatfield D.L. Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J. Biol. Chem. 281 (2006) 13005-13008
36. Yu L.J., Matias J., Scudiero D.A., Hite K.M., Monks A., Sausville E.A., and Waxman D.J. P450 enzyme expression patterns in the NCI human tumor cell line panel. Drug Metab. Dispos. 29 (2001) 304-312
37. Zhang J., Svehlikova V., Bao Y., Howie A.F., Beckett G.J., and Williamson G. Synergy between sulforaphane and selenium in the induction of thioredoxin reductase 1 requires both transcriptional and translational modulation. Carcinogenesis 24 (2003) 497-503
38. Zhang J., Ma K., and Wang H. Cyclophosphamide suppresses thioredoxin reductase in bladder tissue and its adaptive response via inductions of thioredoxin reductase and glutathione peroxidase. Chem.-Biol. Interact. 162 (2006) 24-30